

# Abishek Chandrashekar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1351353/publications.pdf>

Version: 2024-02-01

54  
papers

9,490  
citations

172457

29  
h-index

149698

56  
g-index

71  
all docs

71  
docs citations

71  
times ranked

14947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature, 2021, 590, 630-634.	27.8	995
2	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	12.6	978
3	Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584, 443-449.	27.8	956
4	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	12.6	789
5	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	27.8	765
6	Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science, 2016, 353, 1129-1132.	12.6	461
7	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 2022, 603, 493-496.	27.8	326
8	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.	7.4	307
9	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. New England Journal of Medicine, 2022, 386, 1579-1580.	27.0	296
10	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. Nature, 2021, 596, 268-272.	27.8	290
11	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity, 2017, 46, 1073-1088.e6.	14.3	286
12	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, The, 2018, 392, 232-243.	13.7	269
13	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
14	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature, 2016, 540, 284-287.	27.8	246
15	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature, 2018, 563, 360-364.	27.8	246
16	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. New England Journal of Medicine, 2021, 385, 2010-2012.	27.0	228
17	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS Vaccination. New England Journal of Medicine, 2021, 385, 951-953.	27.0	192
18	Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell, 2017, 169, 610-620.e14.	28.9	191

#	ARTICLE	IF	CITATIONS
19	Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell, 2020, 183, 1354-1366.e13.	28.9	184
20	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science, 2016, 353, 1045-1049.	12.6	129
21	Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Science Translational Medicine, 2017, 9, .	12.4	108
22	Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell, 2021, 184, 3962-3980.e17.	28.9	98
23	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature, 2022, 601, 410-414.	27.8	71
24	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 2022, 185, 1549-1555.e11.	28.9	59
25	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Science Translational Medicine, 2022, 14, eabn6150.	12.4	57
26	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell, 2021, 184, 3467-3473.e11.	28.9	49
27	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	40
28	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature, 2021, 596, 423-427.	27.8	40
29	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nature Medicine, 2021, 27, 1718-1724.	30.7	39
30	Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 1061-1070.	9.1	36
31	Lack of therapeutic efficacy of an antibody to $\text{Î±}4$ $\text{Î²}7$ in SIVmac251-infected rhesus macaques. Science, 2019, 365, 1029-1033.	12.6	31
32	SARS-CoV-2 receptor binding domain displayed on HBsAg virus-like particles elicits protective immunity in macaques. Science Advances, 2022, 8, eabl6015.	10.3	27
33	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nature Communications, 2021, 12, 1474.	12.8	26
34	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	28.9	25
35	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques. Nature Communications, 2021, 12, 5877.	12.8	21
36	Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0.0 rgBT /Overlock 10		

#	ARTICLE	IF	CITATIONS
37	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	12.4	15
38	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1124-1128.	4.0	15
39	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. <i>PLoS Pathogens</i> , 2022, 18, e1010467.	4.7	15
40	Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. <i>Vaccine</i> , 2017, 35, 1-9.	3.8	14
41	Long-acting capsid inhibitor protects macaques from repeat SHIV challenges. <i>Nature</i> , 2022, 601, 612-616.	27.8	14
42	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	12.4	13
43	Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. <i>Nature Communications</i> , 2022, 13, .	12.8	12
44	A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. <i>Med</i> , 2022, 3, 188-203.e4.	4.4	11
45	Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation. <i>Nature Communications</i> , 2020, 11, 5412.	12.8	9
46	Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	8
47	Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13288.	1.2	7
48	Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice. <i>PLoS Pathogens</i> , 2021, 17, e1009673.	4.7	7
49	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
50	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. <i>Journal of Virology</i> , 2022, 96, JVI0159921.	3.4	5
51	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. <i>Npj Vaccines</i> , 2022, 7, 53.	6.0	4
52	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	3
53	Ad26.COVS boosts antibody and T-cell responses following BNT162b2 vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 2220-2222.	6.5	2
54	Passive transfer of Ad26.COVS-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	6.0	2